{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+matched&page=101",
    "query": {
      "intervention": "Placebo- matched",
      "page": 101
    },
    "page_size": 10
  },
  "pagination": {
    "page": 101,
    "page_size": 10,
    "total_count": 7074,
    "total_pages": 708,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+matched&page=102&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+matched&page=100&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-20T06:38:48.416Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02500381",
      "title": "Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "SRP-4045",
          "type": "DRUG"
        },
        {
          "name": "SRP-4053",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sarepta Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "13 Years",
        "sex": "MALE",
        "summary": "6 Years to 13 Years · Male only"
      },
      "enrollment_count": 228,
      "start_date": "2016-09-28",
      "completion_date": "2025-10-16",
      "has_results": false,
      "last_update_posted_date": "2025-11-18",
      "last_synced_at": "2026-11-20T06:38:48.416Z",
      "location_count": 23,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • San Diego, California + 19 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02500381"
    },
    {
      "nct_id": "NCT00570128",
      "title": "Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (HCl) (Aricept) In Treating Cognitive Dysfunction Exhibited By Children With Down Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Down Syndrome"
      ],
      "interventions": [
        {
          "name": "Donepezil HCl",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "10 Years to 17 Years"
      },
      "enrollment_count": 129,
      "start_date": "2007-11-16",
      "completion_date": "2008-09-05",
      "has_results": true,
      "last_update_posted_date": "2021-04-19",
      "last_synced_at": "2026-11-20T06:38:48.416Z",
      "location_count": 31,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 25 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00570128"
    },
    {
      "nct_id": "NCT01934192",
      "title": "Nutritional Adequacy Therapeutic Enhancement in the Critically Ill. The NUTRIATE Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gastroparesis"
      ],
      "interventions": [
        {
          "name": "GSK962040 50 mg",
          "type": "DRUG"
        },
        {
          "name": "Metoclopramide 10 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo NG",
          "type": "DRUG"
        },
        {
          "name": "Placebo IV",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 91,
      "start_date": "2014-04-04",
      "completion_date": "2016-07-08",
      "has_results": true,
      "last_update_posted_date": "2017-12-11",
      "last_synced_at": "2026-11-20T06:38:48.416Z",
      "location_count": 4,
      "location_summary": "Aurora, Colorado • Augusta, Georgia • Louisville, Kentucky + 1 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01934192"
    },
    {
      "nct_id": "NCT02272634",
      "title": "A Phase 2a Study to Assess Safety, Daily Symptoms, PK, and Biomarkers of YPL-001 in COPD Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "YPL-001 80 mg",
          "type": "DRUG"
        },
        {
          "name": "YPL-001 160 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yungjin Pharm. Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "30 Years to 85 Years"
      },
      "enrollment_count": 61,
      "start_date": "2015-06-04",
      "completion_date": "2017-11-08",
      "has_results": true,
      "last_update_posted_date": "2023-07-14",
      "last_synced_at": "2026-11-20T06:38:48.416Z",
      "location_count": 4,
      "location_summary": "Birmingham, Alabama • Winter Park, Florida • Columbus, Ohio + 1 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Winter Park",
          "state": "Florida"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02272634"
    },
    {
      "nct_id": "NCT01117181",
      "title": "Apathy in Dementia Methylphenidate Trial (ADMET)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Apathy",
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Methylphenidate",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "Psychosocial intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Johns Hopkins Bloomberg School of Public Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2010-06",
      "completion_date": "2012-08",
      "has_results": true,
      "last_update_posted_date": "2018-06-12",
      "last_synced_at": "2026-11-20T06:38:48.416Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Charleston, South Carolina",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01117181"
    },
    {
      "nct_id": "NCT03904407",
      "title": "Optimizing Overactive Bladder Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Overactive Bladder"
      ],
      "interventions": [
        {
          "name": "Lactobacillus Probiotic Capsule",
          "type": "OTHER"
        },
        {
          "name": "Matching Lactobacillus Probiotic Placebo Capsule",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 29,
      "start_date": "2019-06-01",
      "completion_date": "2020-05-01",
      "has_results": false,
      "last_update_posted_date": "2020-05-11",
      "last_synced_at": "2026-11-20T06:38:48.416Z",
      "location_count": 2,
      "location_summary": "Hillsborough, North Carolina • Raleigh, North Carolina",
      "locations": [
        {
          "city": "Hillsborough",
          "state": "North Carolina"
        },
        {
          "city": "Raleigh",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03904407"
    },
    {
      "nct_id": "NCT02840799",
      "title": "Effect of KNO3 Compared to KCl on Oxygen UpTake in Heart Failure With Preserved Ejection Fraction (KNO3CK OUT HFPEF)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Heart Failure"
      ],
      "interventions": [
        {
          "name": "Potassium Nitrate (KNO3)",
          "type": "DRUG"
        },
        {
          "name": "Potassium Chloride (KCl)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 84,
      "start_date": "2016-08",
      "completion_date": "2022-08",
      "has_results": true,
      "last_update_posted_date": "2023-12-18",
      "last_synced_at": "2026-11-20T06:38:48.416Z",
      "location_count": 3,
      "location_summary": "Evanston, Illinois • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02840799"
    },
    {
      "nct_id": "NCT04163419",
      "title": "Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schwannomatosis",
        "Pain"
      ],
      "interventions": [
        {
          "name": "Tanezumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2020-04-30",
      "completion_date": "2024-09-30",
      "has_results": false,
      "last_update_posted_date": "2024-03-13",
      "last_synced_at": "2026-11-20T06:38:48.416Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04163419"
    },
    {
      "nct_id": "NCT04269200",
      "title": "Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Endometrial Neoplasms"
      ],
      "interventions": [
        {
          "name": "olaparib",
          "type": "DRUG"
        },
        {
          "name": "durvalumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "durvalumab placebo",
          "type": "DRUG"
        },
        {
          "name": "olaparib placebo",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "150 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 150 Years · Female only"
      },
      "enrollment_count": 805,
      "start_date": "2020-05-05",
      "completion_date": "2027-04-01",
      "has_results": true,
      "last_update_posted_date": "2026-11-05",
      "last_synced_at": "2026-11-20T06:38:48.416Z",
      "location_count": 50,
      "location_summary": "Tucson, Arizona • Concord, California • La Jolla, California + 45 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Santa Barbara",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04269200"
    },
    {
      "nct_id": "NCT03945292",
      "title": "Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alpha 1-Antitrypsin Deficiency"
      ],
      "interventions": [
        {
          "name": "Fazisiran Injection",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Arrowhead Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 40,
      "start_date": "2019-08-07",
      "completion_date": "2023-09-18",
      "has_results": true,
      "last_update_posted_date": "2025-11-04",
      "last_synced_at": "2026-11-20T06:38:48.416Z",
      "location_count": 16,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 13 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03945292"
    }
  ]
}